Xiaodong Shen

TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.

TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.

TL;DR: In this paper, the authors evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer.

TL;DR: PD-L1 expression is prevalent in this disease and may protect cancer cells from immune-mediated degranulation, leading to a poor prognosis and limited treatment options.

TL;DR: MPDL3280A, a human monoclonal Ab containing an engineered Fc-domain designed to inhibit anti-cancer immune responses, is introduced into the clinic for the treatment of lung cancer.